Literature DB >> 12679136

Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.

Solveigh Krusekopf1, Ivar Roots, Ullrich Kleeberg.   

Abstract

Drug-mediated regulation of mRNA expression of all members of the cytochrome P450 3A (CYP3A) subfamily has been measured by reverse transcription-polymerase chain reaction (RT-PCR) in the human hepatocellular carcinoma cell line, HepG2. Transcriptional regulation was proved by inhibition of induction with actinomycin D. Besides the positive control dexamethasone, the H(+)/K(+)-ATPase inhibitors omeprazole, lansoprazole, pantoprazole, and rabeprazole, and the herbal antidepressant St. John's wort (Hypericum extract) were studied. All CYP3A mRNAs were induced by dexamethasone. CYP3A4 was the only CYP3A isoform that was induced by all of the four benzimidazole derivatives, while CYP3A5, CYP3A7, and CYP3A43 were unaffected or even slightly downregulated by these drugs. St. John's wort also increased CYP3A4 mRNA exclusively, leaving CYP3A5 and CYP3A43 unaffected, whereas CYP3A7 was decreased. Depending on the inducer, expression of CYP3A4 is differently regulated from CYP3A5, CYP3A7, and CYP3A43.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679136     DOI: 10.1016/s0014-2999(03)01481-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

Review 1.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

3.  Establishment of a human neonatal hepatocyte cell line.

Authors:  Yvonne Reid; Jaya P Gaddipati; Deepmala Yadav; Judy Kantor
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-06-30       Impact factor: 2.416

Review 4.  Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Authors:  Haixing Li; Jed N Lampe
Journal:  Arch Biochem Biophys       Date:  2019-08-22       Impact factor: 4.013

5.  An efficient method for differentiation of human induced pluripotent stem cells into hepatocyte-like cells retaining drug metabolizing activity.

Authors:  Yuki Kondo; Takahiro Iwao; Katsunori Nakamura; Takamitsu Sasaki; Shogo Takahashi; Noboru Kamada; Tsutomu Matsubara; Frank J Gonzalez; Hidenori Akutsu; Yoshitaka Miyagawa; Hajime Okita; Nobutaka Kiyokawa; Masashi Toyoda; Akihiro Umezawa; Kiyoshi Nagata; Tamihide Matsunaga; Shigeru Ohmori
Journal:  Drug Metab Pharmacokinet       Date:  2013-12-10       Impact factor: 3.614

6.  Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.

Authors:  Chad D Moore; Jessica K Roberts; Christopher R Orton; Takahiro Murai; Trevor P Fidler; Christopher A Reilly; Robert M Ward; Garold S Yost
Journal:  Drug Metab Dispos       Date:  2012-11-09       Impact factor: 3.922

Review 7.  Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.

Authors:  Ogheneochukome Lolodi; Yue-Ming Wang; William C Wright; Taosheng Chen
Journal:  Curr Drug Metab       Date:  2017       Impact factor: 3.731

Review 8.  Drug interactions with St John's wort : mechanisms and clinical implications.

Authors:  Marcus Mannel
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers.

Authors:  Andreas Johne; Elke S Perloff; Steffen Bauer; Jürgen Schmider; Ingrid Mai; Jürgen Brockmöller; Ivar Roots
Journal:  Eur J Clin Pharmacol       Date:  2004-09-15       Impact factor: 2.953

10.  St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive.

Authors:  Liane Will-Shahab; Steffen Bauer; Ullrich Kunter; Ivar Roots; Axel Brattström
Journal:  Eur J Clin Pharmacol       Date:  2008-11-18       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.